Arbutus Biopharma (ABUS) Total Non-Current Liabilities (2011 - 2026)

Arbutus Biopharma's Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 69.33% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (down 69.33% YoY), while the FY2025 annual figure was $14.6 million, down 39.46% from the prior year.
• Total Non-Current Liabilities came in at $8.4 million for Q1 2026 at Arbutus Biopharma, down from $14.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $67.4 million in Q1 2022 to a low of $8.4 million in Q1 2026.
• A 5-year average of $31.5 million and a median of $29.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 429.71% in 2022 and slumped 69.33% in 2026, its largest moves.
• Arbutus Biopharma's Total Non-Current Liabilities stood at $48.2 million in 2022, then plunged by 36.14% to $30.8 million in 2023, then declined by 21.66% to $24.1 million in 2024, then slumped by 39.46% to $14.6 million in 2025, then tumbled by 42.58% to $8.4 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $8.4 million, $14.6 million, and $16.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison